尼克塔尔治疗公司因涉嫌证券欺诈而被起诉. Nektar Therapeutics sued over alleged securities fraud in Phase 2b trial.

尼克塔尔治疗公司面临集体诉讼, 指控其2b期REZOLVE-AA试验涉及证券欺诈. Nektar Therapeutics faces a class action lawsuit alleging securities fraud regarding its Phase 2b REZOLVE-AA trial. 诉讼声称公司误导了招生协议,导致四名不合格的患者被纳入试验时无效. 这造成库存下降. The suit claims the company misrepresented enrollment protocols, leading to an invalid trial when four ineligible patients were included, causing a stock drop. 投资者在2025年2月26日至2025 年12月15日期间购买股票,请于2026年5月5日前与律师联系. Investors who purchased shares between February 26, 2025, and December 15, 2025, are urged to contact counsel by May 5, 2026.